IS4466A - Samsetning og meðhöndlun fyrir heila- og mænusigg - Google Patents

Samsetning og meðhöndlun fyrir heila- og mænusigg

Info

Publication number
IS4466A
IS4466A IS4466A IS4466A IS4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A
Authority
IS
Iceland
Prior art keywords
treatment
composition
multiple sclerosis
sclerosis
Prior art date
Application number
IS4466A
Other languages
English (en)
Inventor
Smilek Dawn
Samson Michael
Gefter Malcolm
Hsu Di-Hwei
Shi Jia-Dong
Paliard Xavier
Devaux Brigitte
Rothbard Jonathan
Franzén Henry
Original Assignee
Immulogic Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corporation filed Critical Immulogic Pharmaceutical Corporation
Publication of IS4466A publication Critical patent/IS4466A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS4466A 1994-10-25 1997-04-17 Samsetning og meðhöndlun fyrir heila- og mænusigg IS4466A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
IS4466A true IS4466A (is) 1997-04-17

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4466A IS4466A (is) 1994-10-25 1997-04-17 Samsetning og meðhöndlun fyrir heila- og mænusigg

Country Status (15)

Country Link
EP (1) EP0787147A1 (is)
JP (1) JPH10504039A (is)
AU (1) AU4278296A (is)
BR (1) BR9509438A (is)
CA (1) CA2203629A1 (is)
CZ (1) CZ122697A3 (is)
FI (1) FI971750A7 (is)
HU (1) HUT77047A (is)
IL (1) IL115766A0 (is)
IS (1) IS4466A (is)
NO (1) NO971900L (is)
PL (1) PL324091A1 (is)
SI (1) SI9520118A (is)
SK (1) SK51297A3 (is)
WO (1) WO1996012737A2 (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
DE69733343D1 (de) 1996-03-21 2005-06-30 Circassia Ltd Kryptische peptide und verfahren zu ihrer identifizierung
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
HK1039636A1 (zh) * 1998-05-05 2002-05-03 科里克萨公司 髓磷脂碱性蛋白肽及其应用
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
WO2003080638A2 (en) 2002-03-27 2003-10-02 Aegera Therapeutics, Inc. Antisense iap nucleobase oligomers and uses thereof
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
US20120082644A1 (en) * 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
WO2011046462A1 (en) 2009-10-12 2011-04-21 Angport Limited Composition for treatment of multiple sclerosis
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (en) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
CN108884140B (zh) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856566T2 (de) * 1987-06-24 2004-06-24 Brigham And Women's Hospital, Boston Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
WO1991008760A1 (en) * 1989-12-20 1991-06-27 Brigham And Women's Hospital Improved treatment of autoimmune diseases by aerosol administration of auto antigens
DE69127470T2 (de) * 1990-03-02 1998-02-19 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
JPH07501526A (ja) * 1991-11-19 1995-02-16 アナージェン，インコーポレイティド 有害な免疫応答の改善において有用なｍｈｃサブユニット結合体
ES2190784T3 (es) * 1992-02-28 2003-08-16 Autoimmune Inc Supresion de enfermedades autoinmunes por antigenos espectadores.
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
IL106720A (en) * 1992-08-17 1998-10-30 Autoimmune Inc The use of antigen bystander in the preparation of compositions for the treatment of neurologically related diseases in mammals and such compositions
CA2170901A1 (en) * 1993-09-03 1995-03-09 Brigitte Devaux Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
CA2172512A1 (en) * 1993-09-22 1995-03-30 Lawrence Steinman Interaction of t-cell receptors and antigen in autoimmune disease
BR9507452A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
JPH09511745A (ja) * 1994-04-08 1997-11-25 ブリガム アンド ウィミンズ ホスピタル 経口寛容および／またはタイプｉインターフェロンを用いた自己免疫疾患の治療
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
CA2192468A1 (en) * 1994-06-09 1995-12-14 Johannes M. Van Noort Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
DE69525544T2 (de) * 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
FI971750A0 (fi) 1997-04-24
CA2203629A1 (en) 1996-05-02
FI971750A7 (fi) 1997-06-24
PL324091A1 (en) 1998-05-11
WO1996012737A3 (en) 1996-10-10
HUT77047A (hu) 1998-03-02
SK51297A3 (en) 1998-03-04
EP0787147A1 (en) 1997-08-06
CZ122697A3 (en) 1997-09-17
WO1996012737A2 (en) 1996-05-02
SI9520118A (sl) 1998-08-31
JPH10504039A (ja) 1998-04-14
NO971900D0 (no) 1997-04-24
IL115766A0 (en) 1996-01-19
BR9509438A (pt) 1997-12-23
NO971900L (no) 1997-06-25
AU4278296A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
FI970859A7 (fi) Metallien käsittelykoostumus ja -prosessi
IS4481A (is) Díhýdrópyramídín og notkun þeirra
DE69607321D1 (de) Reinigungsverfahren und zusammensetzung
NO20035726D0 (no) Benzopyran-inneholdende forbindelser og fremgangsmåte for anvendelse derav
DE69526966D1 (de) Hautkräftigende kometische zusammensetzung
DE69513916D1 (de) Oberflächenbehandlungszusammensetzung
DK0804078T3 (da) Sammensætning og anvendelse deraf
NO943763D0 (no) 4-arylamino-benzopyraner og beslektede forbindelser
FI971750A7 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
FI954773A7 (fi) Antihypertriglyserideeminen koostumus
DE69620642D1 (de) Reiningungsverfahren und-zusammensetzung
FI951060L (fi) Formulaatioita ja hoitomenetelmiä
KR960705557A (ko) 항미생물 방법 및 화장품 조성물(antimicrobial method and cosmetic composition)
DE69622461D1 (de) Oberflächenbehandlungszusammensetzung
BR9510062A (pt) Macromonômeto esterificado e composição
BR9509688A (pt) Composto e composição farmacêutica
IL113661A0 (en) Compositions and treatment for multiple sclerosis
DE69519913D1 (de) Dauerwellenzusammensetzung
ITMI940362A0 (it) Composizione antitosse
GB9415901D0 (en) Novel compounds and treatment
NO972216D0 (no) Acrotein-frigjörende sammensetning og dens anvendelse
GB9415900D0 (en) Novel compounds and treatment
BR9507133A (pt) N-aril e n-alquilsulfonilaminais
NO952766D0 (no) Opplösningsmiddelsammensetninger og metoder